Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy
Frontiers in Bioscience-Landmark · 17.06.2024 · 29 (6)
DOI: 10.31083/j.fbl2906216 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 17.06.2024. Verfasst von Moran Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The treatment options for multiple myeloma (MM) have undergone significant transformation with the advent of immunotherapy. Novel therapies that focus on tumor antigens now drive advances in MM research. Bispecific antibodies (bsAbs) leverage revolutionary advances in bioengineering techniques and embody the second generation of antibody-based tumor therapy. Recent studies on bsAbs in relapsed/refractory MM cases have revealed remarkable efficacy and acceptable safety profiles. The approval of elranatamab and teclistamab represents the next step in the development of bsAbs for the treatment of MM. This review article addresses the antigen targeting, efficacy, safety, and strategies in the application of bsAbs against treatment-resistant MM, with a focus on clinical trials and real-world data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China.
Zitieren
APA
Wang, M., Wang, C., Deng, J., Wang, H., Sun, C., Luo, S., & Hu, Y. (2024). Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy. Frontiers in Bioscience-Landmark, 29(6). https://doi.org/10.31083/j.fbl2906216
Vancouver
Wang M, Wang C, Deng J, Wang H, Sun C, Luo S, et al. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy. Frontiers in Bioscience-Landmark. 2024;29(6). doi:10.31083/j.fbl2906216
BibTeX
@article{Wang2024,
author = {Wang, Moran and Wang, Chaofan and Deng, Jun and Wang, Huafang and Sun, Chunyan and Luo, Shanshan and Hu, Yu},
title = {Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
volume = {29},
number = {6},
doi = {10.31083/j.fbl2906216}
}
EUVIMED